[go: up one dir, main page]

MXPA03003690A - Acidos nucleicos y proteinas de los grupos a y b de estreptococos. - Google Patents

Acidos nucleicos y proteinas de los grupos a y b de estreptococos.

Info

Publication number
MXPA03003690A
MXPA03003690A MXPA03003690A MXPA03003690A MXPA03003690A MX PA03003690 A MXPA03003690 A MX PA03003690A MX PA03003690 A MXPA03003690 A MX PA03003690A MX PA03003690 A MXPA03003690 A MX PA03003690A MX PA03003690 A MXPA03003690 A MX PA03003690A
Authority
MX
Mexico
Prior art keywords
proteins
streptococcus
nucleic acids
streptococcus groups
group
Prior art date
Application number
MXPA03003690A
Other languages
English (en)
Inventor
Claire Fraser
Original Assignee
Chiron Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0026333A external-priority patent/GB0026333D0/en
Priority claimed from GB0028727A external-priority patent/GB0028727D0/en
Priority claimed from GB0105640A external-priority patent/GB0105640D0/en
Application filed by Chiron Spa filed Critical Chiron Spa
Publication of MXPA03003690A publication Critical patent/MXPA03003690A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018—Glutathione transferase (2.5.1.18)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)

Abstract

La invencion proporciona proteinas de estreptococos del grupo B (Streptococcus agalactiae) y estreptococos del grupo A (Streptococcus pyogenes), incluyendo secuencias de aminoacidos y las secuencias de nucleotidos correspondientes. Se ofrecen datos para mostrar que las proteinas son antigenos utiles para vacunas, composiciones inmunogenicas y/o diagnosticos. Las proteinas son tambien blancos para antibioticos.
MXPA03003690A 2000-10-27 2001-10-29 Acidos nucleicos y proteinas de los grupos a y b de estreptococos. MXPA03003690A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0026333A GB0026333D0 (en) 2000-10-27 2000-10-27 Streptococcus antigens
GB0028727A GB0028727D0 (en) 2000-11-24 2000-11-24 Streptococcus antigens
GB0105640A GB0105640D0 (en) 2001-03-07 2001-03-07 Streptococcus proteins
PCT/GB2001/004789 WO2002034771A2 (en) 2000-10-27 2001-10-29 Nucleic acids and proteins from streptococcus groups a & b

Publications (1)

Publication Number Publication Date
MXPA03003690A true MXPA03003690A (es) 2004-05-05

Family

ID=27255953

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA03003690A MXPA03003690A (es) 2000-10-27 2001-10-29 Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
MX2015001810A MX357775B (es) 2000-10-27 2001-10-29 Acidos nucleicos y proteinas de los grupos a y b de estreptococos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015001810A MX357775B (es) 2000-10-27 2001-10-29 Acidos nucleicos y proteinas de los grupos a y b de estreptococos.

Country Status (16)

Country Link
US (10) US7939087B2 (es)
EP (10) EP1671981A3 (es)
JP (5) JP4254931B1 (es)
AT (1) ATE439372T1 (es)
AU (2) AU1412702A (es)
CA (2) CA2425303A1 (es)
CY (1) CY1110698T1 (es)
DE (1) DE60139563D1 (es)
DK (1) DK1328543T3 (es)
ES (1) ES2330083T3 (es)
IL (5) IL154853A0 (es)
MX (2) MXPA03003690A (es)
NZ (6) NZ540544A (es)
SG (1) SG165981A1 (es)
WO (1) WO2002034771A2 (es)
ZA (1) ZA200302739B (es)

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909323B1 (en) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
US7087235B2 (en) * 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
SI1141308T1 (sl) 1998-12-22 2007-08-31 Microscience Ltd Streptokokni proteini skupine B in njihova uporaba
US7491402B2 (en) * 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
KR20020073150A (ko) * 1999-12-23 2002-09-19 브이맥스 리미티드 독성 유전자, 단백질, 및 그 용도
EP1360324A2 (en) 2000-08-31 2003-11-12 Mayo Foundation For Medical Education And Research Detection of varicella-zoster virus
IL154853A0 (en) * 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
US7595057B2 (en) 2000-12-21 2009-09-29 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
US7691571B2 (en) 2001-01-31 2010-04-06 Mayo Foundation For Medical Education And Research Detection of bordetella
US6958210B2 (en) 2001-01-31 2005-10-25 Mayo Foundation For Medical Education And Research Detection of herpes simplex virus
US7482012B2 (en) 2001-02-21 2009-01-27 Id Biomedical Corporation Streptococcus pyogenes polypeptides and corresponding DNA fragments
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
CA2443493A1 (en) 2001-04-13 2002-10-24 Wyeth Surface proteins of streptococcus pyogenes
AU2008207670B2 (en) * 2001-04-13 2011-06-16 Wyeth Surface proteins of streptococcus pyogenes
EP1390505A2 (en) * 2001-05-02 2004-02-25 Shire Biochem Inc. Antigens of group b streptococcus and corresponding dna fragments
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
DE60234772D1 (de) 2001-07-06 2010-01-28 Id Biomedical Corp Gruppe-b streptococcus antigene und entsprechende dna-fragmente
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP4413617B2 (ja) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
WO2003099868A2 (en) * 2002-05-28 2003-12-04 Omrix Biopharmaceuticals Inc. Method for obtaining anti-idiotype antibodies
AU2003246495A1 (en) * 2002-07-15 2004-02-02 Id Biomedical Corporation Polypeptide of streptococcus pyogenes
AU2003250684A1 (en) * 2002-07-31 2004-02-16 Affinium Pharmaceuticals, Inc. Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
BR0313237A (pt) * 2002-08-12 2005-07-12 Akzo Nobel Nv Sequência de ácido nucleico, fragmento de dna, molécula de dna recombinante, veìculo recombinante vivo, célula hospedeira, proteìna de streptococcus uberis, usos da mesma e de uma sequência de ácido nucleico, de um fragmento de dna, de uma molécula de dna recombinante, de um veìculo recombinante vivo, de uma célula hospedeira ou de uma proteìna ou de um fragmento imunogênico da mesma, vacina, método para a preparação da mesma, e, kit diagnóstico
DE10239629A1 (de) * 2002-08-23 2004-04-08 Idt Impfstoffwerk Dessau-Tornau Gmbh Nicht-rekombinate Subunit-Vakzine gegen Streptococcus suis-Infektionen des Schweines
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
US20040081646A1 (en) * 2002-08-29 2004-04-29 Engler Jeffrey A. Group B Streptococcal phage lysin
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2004041157A2 (en) * 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine
US7074598B2 (en) 2002-09-25 2006-07-11 Mayo Foundation For Medical Education And Research Detection of vancomycin-resistant enterococcus spp.
US7365176B2 (en) 2002-09-26 2008-04-29 Mayo Foundation For Medical Education And Research Detection of Epstein-Barr virus
WO2004033709A2 (en) * 2002-10-08 2004-04-22 Emory University Methods, probes, and kits for detecting group a streptococcus
WO2004035618A2 (en) * 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
WO2004039399A1 (en) 2002-11-01 2004-05-13 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
DE10300335B4 (de) * 2003-01-09 2008-06-26 Iep Gmbh Oxidoreduktase
DE602004022923D1 (de) * 2003-03-04 2009-10-15 Intercell Ag Streptococcus pyogenes antigene
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CA2522238A1 (en) 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
CN101864431A (zh) 2003-05-07 2010-10-20 英特塞尔股份公司 无乳链球菌抗原ⅰ和ⅱ
CA2525540A1 (en) * 2003-05-30 2004-12-09 Intercell Ag Enterococcus antigens
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
AU2004253835B2 (en) * 2003-07-04 2009-01-29 Affibody Ab Polypeptides having binding affinity for HER2
WO2005032582A2 (en) 2003-07-31 2005-04-14 Chiron Corporation Immunogenic compositions for streptococcus pyogenes
US20070110763A1 (en) * 2003-08-15 2007-05-17 Stephane Rioux Polypeptides of streptococcus pyogenes
JP4771948B2 (ja) * 2003-09-15 2011-09-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのための免疫原性組成物
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1663303B1 (en) * 2003-09-15 2011-05-04 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus agalactiae
US7427475B2 (en) 2003-11-18 2008-09-23 Mayo Foundation For Medical Education And Research Detection of group B streptococcus
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
ATE510914T1 (de) * 2004-07-02 2011-06-15 Avi Biopharma Inc Antisinn antibakterielle verfahren und verbindungen
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP1780711B1 (en) * 2004-08-17 2012-02-15 Panasonic Corporation Information recording medium, data sorting device, and data reproducing device
TWI377564B (en) * 2004-08-17 2012-11-21 Panasonic Corp Information storage medium and multiplexing device
GB0421465D0 (en) * 2004-09-27 2004-10-27 Chiron Srl Group A streptococcus protein
WO2006042027A2 (en) * 2004-10-08 2006-04-20 Novartis Vaccines And Diagnostics Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US20060223080A1 (en) 2004-11-09 2006-10-05 Gen-Probe Incorporated Compositions and methods for detecting group a streptococci
EP1828231A2 (en) * 2004-12-22 2007-09-05 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus
US7718182B2 (en) 2005-01-21 2010-05-18 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
AU2006212754B2 (en) 2005-02-07 2009-09-03 Gen-Probe Incorporated Compositions and methods for detecting Group B Streptococci
DK1858919T3 (da) 2005-02-18 2012-07-16 Novartis Vaccines & Diagnostic Immunogener fra uropathogen Escherichia coli
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
US8105612B2 (en) 2005-05-13 2012-01-31 Novartis Vaccines And Diagnostics, Inc. Serum resistance factors of gram positive bacteria
FR2886312B1 (fr) * 2005-05-26 2012-12-14 Abag Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a streptococcus pyogenes
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007016938A2 (en) * 2005-07-27 2007-02-15 Stichting Katholieke Universiteit Methods for diagnosing colon cancer and streptococcus bovis proteins for use in the method
AU2006283302B2 (en) * 2005-08-24 2012-11-15 Novartis Vaccines And Diagnostics Srl Zwitterionization of capsular saccharides
EP2357000A1 (en) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1998800A2 (en) 2006-01-18 2008-12-10 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
ATE514794T1 (de) 2006-05-12 2011-07-15 Gen Probe Inc Zusammensetzungen und verfahren für den nachweis von enterokokken-nukleinsäuren
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
CN101490083A (zh) * 2006-07-07 2009-07-22 英特塞尔股份公司 小化脓性链球菌抗原及其用途
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
JP2010508276A (ja) * 2006-10-30 2010-03-18 ノバルティス アーゲー 化膿連鎖球菌のための免疫原性組成物および治療組成物
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2266591A3 (en) 2007-01-12 2012-08-08 Intercell AG Protective proteins of S. agalactiae, combinations thereof and methods of using the same
EP1953247A1 (en) * 2007-01-31 2008-08-06 GC Corporation A method for measuring the number of oral streptococci, and a PCR primers-probe set used for the same
WO2009003291A1 (en) * 2007-07-03 2009-01-08 Mount Sinai Hospital Therapeutics and diagnostics for group a streptococci
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20110250221A1 (en) * 2007-08-24 2011-10-13 University Of Wollongong Group A Streptococcus Pharmaceutical Compositions and Methods Thereof
JP5653215B2 (ja) * 2007-09-12 2015-01-14 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
AU2013203022B2 (en) * 2007-09-12 2015-09-03 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
WO2009076966A2 (en) * 2007-12-19 2009-06-25 Rhovac Aps Rhoc-based immunotherapy
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
DK2235046T3 (da) 2007-12-21 2012-10-29 Novartis Ag Mutante former af streptolysin-O
RU2475496C2 (ru) 2008-02-21 2013-02-20 Новартис Аг МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
US8247170B2 (en) * 2008-05-16 2012-08-21 Medical Diagnostic Laboratories, Llc Detection of penicillin tolerance in Group B Streptococcus: single nucleotide polymorphisms in penicillin binding protein 4
US9545431B1 (en) * 2008-05-23 2017-01-17 The United States Of America, As Represented By The Secretary Of Agriculture Isolated recombinant cDNA
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
AU2009259951A1 (en) * 2008-06-20 2009-12-23 Wyeth Llc Compositions and methods of use of ORF 554 from beta hemolytic Streptococcal strains
PT2349520T (pt) 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Método de purificação para hidrato de carbono de estreptococos grupo a
PE20120116A1 (es) * 2008-11-05 2012-02-18 Wyeth Llc Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta hemolitica (bhs)
CN102481349B (zh) 2009-01-12 2014-10-15 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
SG10201403702SA (en) * 2009-06-29 2014-09-26 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011051917A1 (en) 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
WO2011084549A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CN107353317A (zh) 2010-05-28 2017-11-17 萨勒普塔医疗公司 具有修饰的亚基间键和/或端基的寡核苷酸类似物
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
PT3981427T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
AU2011295938B2 (en) 2010-08-31 2016-01-14 Glaxosmithkline Biologicals S.A. Lipids suitable for liposomal delivery of protein-coding RNA
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
MY163871A (en) 2011-01-20 2017-10-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
EP2688590B1 (en) 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with phospholipids
CN103764121A (zh) 2011-07-06 2014-04-30 诺华股份有限公司 用于递送rna分子的具有有用n:p比的脂质体
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
EP2557424A1 (en) * 2011-08-11 2013-02-13 InGen Biosciences Method for diagnosing Streptococcus, Enterococcus and Pepstostreptococcus genera infections
BR112014004607A2 (pt) 2011-08-31 2017-03-21 Novartis Ag lipossomas peguilados para entrega de rna codificado imunogênico
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
JP2015500204A (ja) 2011-11-18 2015-01-05 サレプタ セラピューティクス， インコーポレイテッド 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
CN103974718A (zh) 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
WO2013114363A2 (en) * 2012-01-30 2013-08-08 Yeda Research And Development Co.Ltd. Antimicrobial agents
US9120111B2 (en) 2012-02-24 2015-09-01 Rain Bird Corporation Arc adjustable rotary sprinkler having full-circle operation and automatic matched precipitation
AU2013224026A1 (en) 2012-02-24 2014-08-21 Novartis Ag Pilus proteins and compositions
ES2706198T3 (es) 2012-03-20 2019-03-27 Sarepta Therapeutics Inc Conjugados de ácido borónico de análogos de oligonucleótidos
GB201206366D0 (en) * 2012-04-11 2012-05-23 Absynth Biologics Ltd Bacterial vaccine
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
CN104321078A (zh) 2012-04-26 2015-01-28 诺华股份有限公司 抗原和抗原组合
ES2820898T3 (es) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Conjugado del serogrupo X de meningococos
RS59199B1 (sr) 2012-05-25 2019-10-31 Univ California Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta
US20150225734A1 (en) 2012-06-19 2015-08-13 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
US9156043B2 (en) 2012-07-13 2015-10-13 Rain Bird Corporation Arc adjustable rotary sprinkler with automatic matched precipitation
EP3400960A1 (en) 2012-09-18 2018-11-14 GlaxoSmithKline Biologicals S.A. Outer membrane vesicles
BR112015007126A2 (pt) 2012-10-02 2017-08-08 Glaxosmithkline Biologicals Sa composição, método para induzir uma resposta imune, e, uso de uma composição
KR20150073943A (ko) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
KR102479178B1 (ko) 2012-12-06 2022-12-19 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-기초된 유전체 변형과 조절
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
EA201891018A1 (ru) 2013-03-08 2018-09-28 Новартис Аг Липиды и липидные композиции для доставки активных агентов
NZ712727A (en) 2013-03-14 2017-05-26 Caribou Biosciences Inc Compositions and methods of nucleic acid-targeting nucleic acids
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
AU2014227831B2 (en) * 2013-03-15 2020-01-30 Regents Of The University Of Minnesota Engineering plant genomes using CRISPR/Cas systems
PL231394B1 (pl) 2013-06-28 2019-02-28 Instytut Immunologii I Terapii Doświadczalnej Im Ludwika Hirszfelda Polskiej Akademii Nauk Test diagnostyczny zakażeń Streptococcus agalactiae
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
WO2015042369A2 (en) * 2013-09-19 2015-03-26 Zoetis Llc Oil-based adjuvants
WO2015070193A1 (en) * 2013-11-11 2015-05-14 Liu Oliver Compositions and methods for targeted gene disruption in prokaryotes
WO2015082501A1 (en) 2013-12-03 2015-06-11 Virometix Ag Proline-rich peptides protective against s. pneumoniae
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
ES2774968T3 (es) 2013-12-19 2020-07-23 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
GB201415602D0 (en) * 2014-09-03 2014-10-15 Moredun Res Inst Streptococcal antigens
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US9951344B2 (en) * 2014-10-10 2018-04-24 Board Of Regents, The University Of Texas System Exogenous terminators for controlling fungal gene expression
US10420826B2 (en) * 2014-11-11 2019-09-24 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
US20180030438A1 (en) 2015-02-23 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US12129471B2 (en) 2015-02-23 2024-10-29 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of human genetic diseases including hemoglobinopathies
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
KR20250073514A (ko) * 2015-06-24 2025-05-27 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
US11130815B2 (en) 2015-06-24 2021-09-28 Jcr Pharmaceuticals Co., Ltd. Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
US9872188B2 (en) * 2015-07-28 2018-01-16 Futurewei Technologies, Inc. Adaptive filtering based network anomaly detection
WO2017031189A1 (en) * 2015-08-17 2017-02-23 Zuchem, Inc. Production of activated tdp-deoxysugars in recombinant microorganisms
CN105112350B (zh) * 2015-09-06 2019-02-01 西北农林科技大学 一种罗伊乳酸杆菌无抗性标记基因整合体系的建立方法及其应用
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
ES2942309T3 (es) 2015-11-04 2023-05-31 Vertex Pharma Materiales y métodos para el tratamiento de hemoglobinopatías
US10652910B2 (en) * 2015-11-05 2020-05-12 Intel IP Corporation Long-term evolution (LTE) and wireless local area network (WLAN) aggregation (LWA) connection procedures
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US11293029B2 (en) 2015-12-07 2022-04-05 Zymergen Inc. Promoters from Corynebacterium glutamicum
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
EP3478845A4 (en) 2016-06-30 2019-07-31 Zymergen, Inc. METHOD OF GENERATING A GLUCOSE PERMEASE LIBRARY AND USES THEREOF
WO2018005655A2 (en) 2016-06-30 2018-01-04 Zymergen Inc. Methods for generating a bacterial hemoglobin library and uses thereof
GB2568182A (en) 2016-08-03 2019-05-08 Harvard College Adenosine nucleobase editors and uses thereof
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN106169969B (zh) * 2016-08-31 2020-01-10 华为技术有限公司 建立虚拟专用网标签交换路径方法、相关设备和系统
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018124107A1 (ja) 2016-12-26 2018-07-05 Ｊｃｒファーマ株式会社 Ｂｄｎｆを含む融合蛋白質
TWI761413B (zh) 2016-12-26 2022-04-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
CN108624516B (zh) * 2017-03-20 2022-08-26 华东理工大学 一种提高发酵细胞中的代谢产物量及制备idms标准品的方法
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
BR112019022164A2 (pt) * 2017-04-26 2020-05-12 Auckland Uniservices Limited Composições e métodos analíticos e terapêuticos e usos dos mesmos
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
SG11202005147WA (en) 2017-12-05 2020-06-29 Vertex Pharma Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
PL239045B1 (pl) * 2018-01-09 2021-11-02 Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk Epitop specyficzny dla zakaźnych Streptococcus agalactiae oraz sposób wykrywania zakażenia pacjenta szczepem Streptococcus agalactiae
EP3749767A1 (en) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
US11268077B2 (en) 2018-02-05 2022-03-08 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
US11458151B2 (en) 2018-02-12 2022-10-04 Inimmune Corporation Toll-like receptor ligands
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN109064036B (zh) * 2018-08-08 2021-07-06 武汉大学 面向管理领域的生态系统服务供需指数变化检测方法
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
AU2020240109A1 (en) 2019-03-19 2021-09-30 President And Fellows Of Harvard College Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
MX2021013736A (es) 2019-05-10 2021-12-10 Glaxosmithkline Biologicals Sa Produccion de conjugados.
CN110489587B (zh) * 2019-07-31 2023-04-28 西安邮电大学 局部梯度方向三值模式的轮胎痕迹图像特征提取方法
US10948568B1 (en) * 2019-09-12 2021-03-16 Cypress Semiconductor Corporation Radar detection in a wireless LAN
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CN111048833B (zh) * 2019-10-30 2022-04-26 深圳市卓能新能源股份有限公司 一种高电压电解液及高电压锂离子动力电池
WO2021222877A1 (en) * 2020-05-01 2021-11-04 Atex Technologies, Inc. Fray resistant structure
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
CN111518857B (zh) * 2020-06-11 2025-10-24 江苏海飞生物科技有限公司 酶法生产氨基葡萄糖盐及其提纯方法
WO2021250625A2 (en) * 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Gbs ferritin nanoparticles
BR112023006710A2 (pt) 2020-10-14 2023-10-03 George Mason Res Foundation Inc Métodos de fabricação de nanopartícula lipídica e composições derivadas da mesma
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用
US12343748B2 (en) 2021-03-16 2025-07-01 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method
US20240285746A1 (en) * 2021-06-01 2024-08-29 The Regents Of The University Of California Protective vaccine antigen against streptococcal infection
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
US12434252B2 (en) 2022-04-20 2025-10-07 Rain Bird Corporation Full-circle and part-circle rotor sprinkler
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
US12440855B2 (en) 2022-10-27 2025-10-14 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion

Family Cites Families (312)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2386796A (en) 1942-08-05 1945-10-16 Bond Crown & Cork Co Extruding device
US3676548A (en) * 1970-09-18 1972-07-11 Lilly Co Eli Method of vaccinating swine against jowl abscess disease
DE2855719A1 (de) 1978-12-22 1980-07-10 Siemens Ag Zahnaerztliche handstueckanordnung
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
AU8300282A (en) 1981-04-29 1982-11-04 Biogen N.V. Bacillus cloning vectors and method of expressing foreign dna
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4454121A (en) 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
EP0114787B1 (de) * 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
US4659561A (en) * 1983-02-18 1987-04-21 The University Of Vermont And State Agricultural College Process for treating the oral cavity
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
ATE78293T1 (de) 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (en) 1983-10-03 1986-12-30 Genentech, Inc. A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
EP0164556B1 (en) 1984-05-11 1994-03-02 Chiron Corporation Enhanced yeast transcription employing hybrid promoter region constructs
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA1260858A (en) 1985-03-28 1989-09-26 Lawrence S. Cousens Expression using fused genes providing for protein product
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6103243A (en) * 1985-05-15 2000-08-15 Biotechnology Australia Pty, Ltd Oral vaccines
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
EP0244042B1 (en) 1986-05-02 1994-08-17 Gist-Brocades N.V. Secretory signal selection vectors for extracellular protein synthesis in bacilli
GB8618443D0 (en) * 1986-07-29 1986-09-03 Univ London Monoclonal antibodies
DE3752372T2 (de) 1986-10-02 2004-06-24 Massachusetts Institute Of Technology, Cambridge Verfahren zur regulierung der metabolischen stabilität von proteinen
AU8108587A (en) * 1986-10-08 1988-05-06 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE103333T1 (de) 1987-03-23 1994-04-15 Zymogenetics Inc Hohe proteinsyntheserate in hefe.
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
EP0318216B2 (en) 1987-11-18 2001-08-29 Chiron Corporation NANBV diagnostics
SE456639B (sv) 1987-11-27 1988-10-24 Golf Comback Ab C O Wiklund Golftraeningsanordning innefattande ett hus med lintrumma
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4973551A (en) 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
US5098827A (en) 1988-02-26 1992-03-24 The University Of Florida Novel bacterial markers for pathogenic group B streptococci
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
JPH03504079A (ja) 1988-03-21 1991-09-12 カイロン　コーポレイション 組換えレトロウィルス
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
GB8827038D0 (en) 1988-11-18 1988-12-21 Kehoe M Streptolysin o antigens & uses
US5354846A (en) 1988-11-18 1994-10-11 Michael Kehoe Streptolysin O antigen derivatives, its production and uses
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
JP3237842B2 (ja) 1988-12-16 2001-12-10 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
GB2233977B (en) 1989-01-04 1993-03-31 Michael Kehoe Cytolytic streptolysin o mutants and uses
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
CA2045129A1 (en) 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
US5364780A (en) 1989-03-17 1994-11-15 E. I. Du Pont De Nemours And Company External regulation of gene expression by inducible promoters
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2357538A1 (en) 1989-03-21 1990-10-04 Wisconsin Alumni Research Foundation Expression of exogenous polynucleotide sequences in a vertebrate
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991002825A1 (en) 1989-08-15 1991-03-07 Pasminco Australia Limited Absorption of zinc vapour in molten lead
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5821088A (en) 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
US6737521B1 (en) 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
WO1992005266A2 (en) 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
WO1992007945A1 (en) 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
CA2098849C (en) 1990-12-20 2007-07-10 Ralph R. Weichselbaum Control of gene expression by ionizing radiation
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
US5391712A (en) 1991-08-30 1995-02-21 Beckman Instruments, Inc. Non-hemolytic streptolysin O variants
US5378620A (en) 1991-08-30 1995-01-03 Beckman Instruments, Inc. Streptolysin O derivatives
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
JPH07503372A (ja) 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION.
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
AU692423B2 (en) 1992-09-25 1998-06-11 Institut National De La Sante Et De La Recherche Medicale Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
EP1321526A3 (en) 1992-11-18 2003-07-02 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
DE4240056A1 (de) 1992-11-28 1994-06-01 Boehringer Mannheim Gmbh Streptolysin O Peptidantigene und Verfahren zur Bestimmung von Streptolysin-Antikörper
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
FI93733C (fi) * 1993-01-29 1995-05-26 Kaarina Tikkanen Streptococcus suis-bakteerin adhesiiniproteiini ja menetelmä sen valmistamiseksi
ES2217258T3 (es) 1993-02-01 2004-11-01 Beckman Coulter Inc Factor mitogeno, gen del mismo y procedimiento para su microdeteccion.
US5348358A (en) 1993-02-22 1994-09-20 Selick David A Contact lens insertion tool
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
DE69419966T2 (de) * 1993-05-17 2000-01-20 Akzo Nobel N.V., Arnheim/Arnhem Impstoff gegen Streptococcus suis-Infektion
JPH09501309A (ja) 1993-05-26 1997-02-10 アメリカ合衆国 アデノ関連性ウイルスレプタンパク質および細菌性タンパク質含有融合タンパク質
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3644961B2 (ja) 1993-06-23 2005-05-11 ベックマン コールター インコーポレイテッド ストレプトコッカス・ピオゲネスから誘導された組換えｄｎアーゼｂ
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
DE69435108D1 (de) 1993-07-13 2008-08-14 Centelion Defekte adenovirus-vektoren und deren verwendung in der gentherapie
CA2167706A1 (en) 1993-07-27 1995-02-09 Nigel Fraser Modified dna virus vectors and uses therefor
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
CA2158937C (en) 1993-09-15 2006-01-03 Thomas W. Dubensky, Jr. Recombinant alphavirus vectors
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
CA2171109A1 (en) 1993-10-01 1995-04-13 Zvi Ram Gene therapy of the nervous system
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
DK0729351T3 (da) 1993-11-16 2000-10-16 Skyepharma Inc Vesikler med reguleret afgivelse af aktivstoffer
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5585098A (en) 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH07241786A (ja) 1994-03-08 1995-09-19 Fanuc Ltd 産業用ロボットの制御装置
US6780406B1 (en) 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
WO1995029993A1 (en) 1994-04-28 1995-11-09 The University Of Michigan Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
FR2723588B1 (fr) 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour la glutathion peroxydase
DE69534186T2 (de) * 1994-09-14 2006-03-09 Baylor College Of Medicine, Houston Impfstoff gegen Streptokokkeninfektionen der Gruppe A
ES2240979T3 (es) 1994-10-07 2005-10-16 Rockefeller University Enzima para la escision de la region de anclaje de las proteinas superficiales de bacterias gram positivas.
AUPM885194A0 (en) 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
AU5741996A (en) 1995-05-22 1996-12-11 Chiron Corporation Position-specific integration of vector constructs into eukaryotic genomes mediated by a chimeric integrase protein
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6936259B2 (en) 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
US6346392B1 (en) * 1996-11-27 2002-02-12 Smithkline Beecham Corporation Polynucleotides encoding a novel glutamine transport ATP-binding protein
IES960488A2 (en) * 1996-07-03 1997-11-19 Trinity College Dublin Subunit Vaccine for Streptococcus Equi
US5945278A (en) * 1996-07-08 1999-08-31 The Finnish National Public Health Institute Method and system for enhanced production of commercially important exoproteins in gram-positive bacteria
EP0821070A1 (en) 1996-07-22 1998-01-28 Carelli, Claude Marcel Henri Pit-1 gene polymorphism and trait selection in animals
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
WO1998006437A2 (en) 1996-08-13 1998-02-19 Chiron Corporation Compositions and methods for polynucleotide delivery
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0942983B2 (en) * 1996-10-31 2014-09-10 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
WO1998019689A1 (en) 1996-11-01 1998-05-14 Smithkline Beecham Corporation Novel coding sequences
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US7033765B1 (en) 1997-02-20 2006-04-25 Toronto Research Chemicals, Inc. Site-specific drug delivery
DE69830305T2 (de) 1997-02-20 2006-02-02 Dime, David S., Toronto Ortsspezifische arzneimittel verabreichung
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
CA2289116A1 (en) 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
EP2085090A3 (en) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
AU751009B2 (en) 1997-09-12 2002-08-08 University Of Tennessee Research Corporation, The Group A streptococcal vaccines
US6716433B1 (en) * 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
WO1999016882A1 (en) * 1997-09-26 1999-04-08 Medimmune, Inc. LMB GENE OF $i(STREPTOCOCCUS AGALACTIAE)
US6406883B1 (en) 1997-09-26 2002-06-18 Luetticken Rudolf Lmb gene of Streptococcus agalactiae
IL134923A0 (en) 1997-10-17 2001-05-20 Nestle Sa Novel lactic acid bacteria species
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
AU762606B2 (en) 1997-11-21 2003-06-26 Genset S.A. Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO1999026969A1 (en) 1997-11-21 1999-06-03 University Of Otago Zoocin a immunity factor
WO1999028475A2 (en) 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
EP1042480A1 (en) 1997-12-31 2000-10-11 Stressgen Biotechnologies Corporation Streptococcal heat shock proteins of the hsp60 family
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
US7041814B1 (en) 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
EP1054971B1 (en) 1998-02-20 2006-12-06 ID Biomedical Corporation Group b streptococcus antigens
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9808327D0 (en) 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
US7183097B1 (en) * 1998-05-07 2007-02-27 Universite Libre De Bruxelles Cytotoxin-based biological containment
US6660520B2 (en) 1998-06-05 2003-12-09 Smithkline Beecham Corporation Nrde
PL204863B1 (pl) * 1998-07-22 2010-02-26 Stichting Dienst Landbouwkundi Zastosowanie mutanta Streptococcus, szczepionka i sposoby kontrolowania lub eliminowania choroby paciorkowcowej w populacji
ATE361365T1 (de) 1998-07-27 2007-05-15 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
US6936252B2 (en) 1998-07-27 2005-08-30 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
WO2000006736A2 (en) 1998-07-27 2000-02-10 Microbial Technics Limited Nucleic acids and proteins from group b streptococcus
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU1202200A (en) 1998-10-09 2000-05-01 Chiron Corporation Neisseria genomic sequences and methods of their use
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7063850B1 (en) * 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
GB9828880D0 (en) * 1998-12-31 1999-02-17 Actinova Ltd Protein
IL145043A0 (en) 1999-03-19 2002-06-30 Smithkline Beecham Biolog Vaccine
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
US7101692B2 (en) 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
WO2000062804A2 (en) 1999-04-15 2000-10-26 The Regents Of The University Of California Identification of sortase gene
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
AU5755500A (en) 1999-06-21 2001-01-09 University Of Utah Research Foundation Isolated genes from virulent group B streptococcus agalactiae
US6833356B1 (en) 1999-08-25 2004-12-21 Medimmune, Inc. Pneumococcal protein homologs and fragments for vaccines
GB9921125D0 (en) * 1999-09-07 1999-11-10 Microbial Technics Limited Proteins
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
CA2383110A1 (en) 1999-09-24 2001-03-29 Veronique Henderickx Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant
WO2001022920A2 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
US6777547B1 (en) 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
CA2404260A1 (en) 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
EP1297145B1 (en) 2000-07-06 2008-10-29 ID Biomedical Corporation Streptococcus pyogenes antigen
US6620585B1 (en) * 2000-08-02 2003-09-16 Elitra Pharmaceuticals, Inc. Use of ectoenzymes and secreted enzymes to monitor cellular proliferation
AU2001281168A1 (en) 2000-08-08 2002-02-18 St. Jude Children's Research Hospital Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
FR2814754B1 (fr) * 2000-10-04 2005-09-09 Pasteur Institut Listeria innocua, genome et applications
US20020086023A1 (en) 2000-10-10 2002-07-04 University Of Tennessee Research Corporation Streptococcal streptolysin S vaccines
US7160547B2 (en) 2000-10-10 2007-01-09 University Of Tennessee Research Corporation Streptococcal streptolysin S vaccines
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
CA2443493A1 (en) 2001-04-13 2002-10-24 Wyeth Surface proteins of streptococcus pyogenes
US20070128229A1 (en) 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
FR2824074A1 (fr) * 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
EP1399181B1 (en) 2001-05-18 2012-05-09 The Government of the USA, as represented by the Secretary, Dept. of Health and Human Services, Centers for Disease Control and Prevention Peptide vaccines against group a streptococci
DE60234772D1 (de) * 2001-07-06 2010-01-28 Id Biomedical Corp Gruppe-b streptococcus antigene und entsprechende dna-fragmente
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10136578B4 (de) * 2001-07-27 2005-05-04 Micronas Gmbh Verfahren zum Prüfen eines Chips mit einem Gehäuse und zum Bestücken einer Platine mit dem Gehäuse sowie Chip mit einem Gehäuse
US20060073530A1 (en) 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
AU2002365223A1 (en) * 2001-10-26 2003-09-02 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
JP2005514052A (ja) * 2001-12-21 2005-05-19 チルドレンズ ホスピタル アンド レジオナル メディカル センター Ｂ群連鎖球菌の新規の細胞表面プロテアーゼの使用
MXPA04006322A (es) * 2001-12-27 2004-10-04 Taisho Pharmaceutical Co Ltd Derivados de 6-fluorobiciclo[3.1.0]hexano.
EP1472353B1 (en) 2002-02-11 2012-02-01 ID Biomedical Corporation Group b streptococcus antigen
GB2385274B (en) 2002-02-13 2004-04-14 Ming-Jeng Shue Vaginal suppository delivery device
US6593093B1 (en) * 2002-02-20 2003-07-15 Mayo Foundation For Medical Education And Research Detection of group a Streptococcus
US20050181388A1 (en) 2002-04-02 2005-08-18 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
AU2003213949A1 (en) 2002-04-08 2003-10-27 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in membrane biogenesis
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
WO2004018646A2 (en) 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
WO2004041157A2 (en) 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine
TW566366U (en) 2002-09-27 2003-12-11 Wus Tech Co Ltd Labor-saving portable battery equipment for power-driven walking assisted scooter
WO2004035618A2 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
DE602004022923D1 (de) 2003-03-04 2009-10-15 Intercell Ag Streptococcus pyogenes antigene
US20060134640A1 (en) * 2003-04-22 2006-06-22 Institut Pasteur Inhibiting the growth of bacterial biofilms
CN101864431A (zh) 2003-05-07 2010-10-20 英特塞尔股份公司 无乳链球菌抗原ⅰ和ⅱ
US20050016201A1 (en) 2003-07-22 2005-01-27 Ivanov Igor C. Multi-staged heating system for fabricating microelectronic devices
WO2005032582A2 (en) 2003-07-31 2005-04-14 Chiron Corporation Immunogenic compositions for streptococcus pyogenes
AU2003904237A0 (en) 2003-08-08 2003-08-21 Garvan Institute Of Medical Research Novel translocation assay
EP1663303B1 (en) 2003-09-15 2011-05-04 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus agalactiae
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1721283B1 (en) 2004-02-06 2022-11-30 Council of Scientific and Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
WO2005108419A1 (en) 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
CA2580343A1 (en) * 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics, Inc. Imidazoquinoline compounds
GB0421465D0 (en) 2004-09-27 2004-10-27 Chiron Srl Group A streptococcus protein
AU2005335216A1 (en) 2004-10-05 2007-02-15 Wyeth Probe arrays for detecting multiple strains of different species
WO2006042027A2 (en) 2004-10-08 2006-04-20 Novartis Vaccines And Diagnostics Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
EP1828231A2 (en) 2004-12-22 2007-09-05 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SI2351772T1 (sl) * 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
US8105612B2 (en) 2005-05-13 2012-01-31 Novartis Vaccines And Diagnostics, Inc. Serum resistance factors of gram positive bacteria
AU2006283302B2 (en) * 2005-08-24 2012-11-15 Novartis Vaccines And Diagnostics Srl Zwitterionization of capsular saccharides
EP1770171A1 (en) 2005-09-29 2007-04-04 Universität Zu Köln DNA microarray for rapid identification of Candida albicans in blood cultures.
GB0522303D0 (en) 2005-11-01 2005-12-07 Chiron Srl Culture method
CA2630220C (en) * 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
DK176565B1 (da) 2006-02-03 2008-09-08 Quilts Of Denmark As Möbelben med lys
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
CN101490083A (zh) 2006-07-07 2009-07-22 英特塞尔股份公司 小化脓性链球菌抗原及其用途
EP2063911A2 (en) * 2006-07-26 2009-06-03 Novartis Ag Immunogenic compositions for gram positive bacteria
JP2010508276A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 化膿連鎖球菌のための免疫原性組成物および治療組成物
JP5653215B2 (ja) * 2007-09-12 2015-01-14 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
DK2235046T3 (da) * 2007-12-21 2012-10-29 Novartis Ag Mutante former af streptolysin-O

Also Published As

Publication number Publication date
CA2425303A1 (en) 2002-05-02
EP1328543A2 (en) 2003-07-23
EP2277896A1 (en) 2011-01-26
EP2277895A1 (en) 2011-01-26
US20060258849A1 (en) 2006-11-16
AU1412702A (en) 2002-05-06
EP2189473A3 (en) 2010-08-11
US20060210579A1 (en) 2006-09-21
NZ594877A (en) 2012-07-27
WO2002034771A3 (en) 2003-01-16
DK1328543T3 (da) 2009-11-23
CA2881568A1 (en) 2002-05-02
US20180094033A1 (en) 2018-04-05
JP2016026494A (ja) 2016-02-18
CA2881568C (en) 2019-09-24
IL154853A (en) 2010-06-16
SG165981A1 (en) 2010-11-29
JP4874323B2 (ja) 2012-02-15
US20100105865A1 (en) 2010-04-29
JP4254931B1 (ja) 2009-04-15
JP2013165714A (ja) 2013-08-29
US10428121B2 (en) 2019-10-01
US20060210581A1 (en) 2006-09-21
NZ560966A (en) 2010-06-25
JP2009118848A (ja) 2009-06-04
US20160264632A1 (en) 2016-09-15
US8137673B2 (en) 2012-03-20
IL202254A (en) 2016-02-29
IL238319A0 (en) 2015-06-30
EP2284181A1 (en) 2011-02-16
US8025890B2 (en) 2011-09-27
IL264925A (en) 2019-05-30
ES2330083T3 (es) 2009-12-04
IL238319B (en) 2019-03-31
EP2189473A2 (en) 2010-05-26
NZ583028A (en) 2011-10-28
US20060210582A1 (en) 2006-09-21
EP1671981A3 (en) 2006-07-05
EP1671981A2 (en) 2006-06-21
US9840538B2 (en) 2017-12-12
NZ524888A (en) 2006-09-29
US20150368304A1 (en) 2015-12-24
DE60139563D1 (de) 2009-09-24
ATE439372T1 (de) 2009-08-15
AU2002214127B2 (en) 2007-06-07
NZ540544A (en) 2007-08-31
NZ593617A (en) 2012-04-27
EP1328543B1 (en) 2009-08-12
WO2002034771A2 (en) 2002-05-02
US7955604B2 (en) 2011-06-07
MX357775B (es) 2018-07-20
EP2284182A1 (en) 2011-02-16
EP2284183A1 (en) 2011-02-16
ZA200302739B (en) 2005-01-26
EP2277894A1 (en) 2011-01-26
JP2010508808A (ja) 2010-03-25
US7939087B2 (en) 2011-05-10
EP2277895B1 (en) 2013-08-14
US9738693B2 (en) 2017-08-22
CY1110698T1 (el) 2015-06-10
US8431139B2 (en) 2013-04-30
IL154853A0 (en) 2003-10-31
EP2896629A1 (en) 2015-07-22
HK1153754A1 (en) 2012-04-05
US20060210580A1 (en) 2006-09-21
JP2011239783A (ja) 2011-12-01
US20130129740A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
MX357775B (es) Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
WO2003093306A3 (en) Nucleic acids and proteins from streptococcus groups a & b
WO2002094868A3 (en) Staphylococcus aureus proteins and nucleic acids
WO2002077021A3 (en) Streptococcus pneumoniae proteins and nucleic acids
NZ532665A (en) Neisseria meningitidis antigens and compositions
WO2002079243A3 (en) Gonococcal proteins and nucleic acids
NO20020348L (no) Peptid acceptor ligeringsmetoder
EP1559795A3 (en) Neisseria genomic sequences and methods of their use
BR9906927A (pt) Proteìnas de neisseria meningitidis
WO2003028656A3 (en) Adjuvant compositions
MXPA01011047A (es) Secuencias genomicas de neisseria y metodos para su uso.
EP1300468A3 (en) TRNA synthetase
WO2001046224A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO1998039450A3 (de) Oberflächenprotein (spsa-protein) von streptococcus pneumoniae deletierte abkömmlinge, expressionssssystem für diese proteine und vaccine mit den proteinen
WO2002083727A3 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
EP0854187A3 (en) Novel glucose 6-phosphate dehydrogenase gene
WO2002026784A3 (en) Matrix proteins m1 and m2 of infections salmon anaemia virus
WO2000046242A3 (en) 19 KILODALTON PROTEIN OF $i(HELICOBACTER PYLORI)
EP0894859A3 (en) Asparaginyl tRNA synthetase from Streptococcus pneumoniae

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status